Patrick Campbell

A new study from the National Center for Global Health and Medicine in Japan has found thiazide use in diabetics with well-controlled blood pressure led to an increased risk of MACE, particularly stroke.

RedHill Biopharma Ltd. has received FDA approval for RHB-105 (Talicia) for the treatment of Helicobacter pylori in adults.

A new analysis of the Paris Prospective Study III has revealed physical activity at work and physical activity from sport have very different effects on cardiovascular health.

Maria Woodward, MD, MSc, discusses the impact of reducing opioid prescriptions following corneal surgery.

A new study of cohorts in Sweden found exposure to black carbon from traffic exhaust was linked to an increased risk of stroke incidence later in life.

Hahn will replace Ned Sharpless, MD, who took over after former commissioner Scott Gottlieb stepped away from the role earlier this year.

A new Mayo Clinic study has found that patients with microvascular endothelial dysfunction were more than twice as likely to be diagnosed with solid-tumor cancer than their counterparts without dysfunction.

A new study from Icahn School of Medicine at Mount Sinai found increases in exposure to fine particulate matter before birth were associated with heart rate variability during infancy.

A new study from researchers at Penn Medicine and CHOP found bariatric surgery is not only effective, but safe for morbidly obese adolescents.

Moira Gunn, PhD, professor of bioentrepreneurship at the University of San Francisco, discusses the biggest hurdles those in healthcare face when looking to create new therapies for rare diseases.

Dawn Rotellini, COO of the National Hemophilia Foundation, discusses how recent policy changes seeking to improve access to and create new therapies for patients with rare diseases.

A review of novel drug approvals in 2018 found more than half of all novel approvals were for rare diseases and that 2018 also saw more novel drug approvals for rare disease than any other year.

Dawn Rotellini, chief operating officer of the National Hemophilia Foundation, discusses the important of including patient advocacy groups in annual meetings such as the NORD Summit.

A new analysis of an open-label extension study of the phase 3 PREVENT study is providing further evidence of the safety and efficacy of the treatment of the neuromyelitis optica spectrum disorder.

A new study presented at NORD Summit 2019 found rare disease is underrepresented in published literature and, more often than not, articles are not available in open-access journals.

Moira Gunn, PhD, professor of bioentrepreneurship at the University of San Francisco, discusses why it is important for primary care providers to keep up-to-date on rare disease developments.

Dawn Rotellini, chief operating officer of the National Hemophilia Foundation, discusses the impact recent advances in technology and changes in policy focusing on rare diseases have impacted the disease state of hemophilia.

Lucas Kempf, MD, associate director of the FDA's Rare Diseases Program, discusses the impact of recent policy changes that center around increasing access to and creating new therapies for rare disease.

AstraZeneca announced approval of the SGLT2 inhibitor for the reduction of hospitalization for heart failure in type 2 diabetes patients in a release on Monday.

Ustekinumab (Stelara) has received approval from the US Food and Drug Administration for the treatment of moderate to severely active ulcerative colitis in adults.

The US Food and Drug Administration has approved minocycline topical foam, 4% for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgarism in adults and pediatrics patients 9 years of age or older.

Katherine Talcott, MD, of Cole Eye Institute, discusses results of a 5-year study examining endogenous bacterial endophthalmitis at a tertiary care center from AAO 2019.

Sumayya Ahmad, MD, assistant professor of medicine at Icahn School of Medicine at Mount Sinai, discusses results of a study she presented at AAO 2019 that examined the real-world survival rates of penetrating keratoplasty.

Katherine Talcott, MD, of the Cole Eye Institute, discusses the results of a study she co-authored from AAO 2019 that examined visual acuity outcomes after cataract extraction with IOL implantation with diabetic eyes.

Rishi Singh, MD, of the Cole Eye Institute, discusses the results of an analysis of VIEW trial participants he presented at AAO 2019.

Sumayya Ahmad, MD, assistant professor of ophthalmology at Icahn School of Medicine at Mount Sinai, discusses the results of a study she co-authored examining demographic associations with varying forms of astigmatism

Michael Stewart, MD, of Mayo Clinic Jacksonville, discusses the results of 2 phase 2a studies examining the use of AKST4290 in treatment naive and refractory neovascular age-related macular degeneration.

Aleksandra Rachitskaya, MD, of Cole Eye Institute, discusses a presentation she led at AAO 2019 on novel imaging and surgical techniques.

A new study has found that receiving or not receiving topical antibiotics following cataract surgery had no impact on the development of endophthalmitis.

A phase 1b study, which was presented by Charles Wykoff, MD, PhD, at AAO 2019, found the novel anti-VEGF therapy KSI-301 shows promise for treating a slew of retinal diseases.